Dr Ronald Eugene Gibson, MD in Casper, WY - Ophthalmology

Dr Ronald Eugene Gibson, MD is a Ophthalmology physician based in Casper, Wyoming. Dr Ronald Eugene Gibson is licensed to practice in Wyoming (license number 3401A) and his current practice location is 1705 E 12th St, Casper, Wyoming. He can be reached at his office (for appointments etc.) via phone at (307) 235-4185.

NPI number for Dr Ronald Eugene Gibson is 1629129739 and his current mailing address is 1705 E 12th St, Casper, Wyoming. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1629129739.

Contact Information

	Dr Ronald Eugene Gibson, MD
	1705 E 12th St, Casper, WY 82601-4038
	(307) 235-4185
	(307) 235-4127

Physician's Profile

Full Name	Dr Ronald Eugene Gibson
Gender	Male
Speciality	Ophthalmology
Location	1705 E 12th St, Casper, Wyoming
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1629129739
Provider Enumeration Date: 01/15/2007
Last Update Date: 11/04/2010

Medical Identifiers

Medical identifiers for Dr Ronald Eugene Gibson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1629129739	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207W00000X	Ophthalmology	3401A (Wyoming)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Ronald Eugene Gibson is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Ronald Eugene Gibson, MD 1705 E 12th St, Casper, WY 82601-4038 Ph: (307) 235-4185	Dr Ronald Eugene Gibson, MD 1705 E 12th St, Casper, WY 82601-4038 Ph: (307) 235-4185

News Archive

EpiCept enters definitive agreements to purchase 8.9 million shares of common stock

EpiCept Corporation announced today that it has entered into definitive agreements for the purchase of approximately 8.9 million shares of its common stock at $0.80 per share, and five-year warrants to purchase up to approximately 3.6 million shares of common stock at an exercise price of $0.75 per share.

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Adeona Pharmaceuticals, Inc. announced its second quarter 2010 financial results and recent achievements.

Vaccination efforts in poor countries prevent 20 million deaths, provide economic benefits

Vaccination efforts made in the world's poorest countries since 2001 will have prevented 20 million deaths and saved $350 billion in health-care costs by 2020, according to a new study from the University of North Carolina at Chapel Hill.

Dr Ronald Eugene Gibson, MD - Ophthalmology in Casper, WY